MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
In this episode, Isabelle Petit, senior manager at Debiopharm, a leading development company headquartered in Lausanne, Switzerland, discusses the latest data from a clinical trial of a three-month formulation for acromegaly treatment, highlighting its impact on patient quality of life and treatment satisfaction.
In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly.
Oxytocin is classically known for its role in labor and breastfeeding; however, a growing body of literature has demonstrated oxytocin’s role in several physiologic domains both in animal models and humans. Oxytocin, in fact, regulates metabolism, mood, social functioning, sexual function, and bone and muscular health.
